BioLife Solutions Net Income Over Time
| BLFS Stock | USD 22.36 0.13 0.58% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioLife Solutions Performance and BioLife Solutions Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will BioLife introduce new products? Factors like these will boost the valuation of BioLife Solutions. Projected growth potential of BioLife fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about BioLife Solutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.4 | Earnings Share (0.38) | Revenue Per Share | Quarterly Revenue Growth 0.312 | Return On Assets |
Investors evaluate BioLife Solutions using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating BioLife Solutions' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause BioLife Solutions' market price to deviate significantly from intrinsic value.
It's important to distinguish between BioLife Solutions' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioLife Solutions should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, BioLife Solutions' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare BioLife Solutions and related stocks such as Kestra Medical Techn, Novocure, and Azenta Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KMTS | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (34.1 M) | (84.2 M) | (84.2 M) | (94.1 M) | (113.8 M) | (102.4 M) | (107.6 M) |
| NVCR | (77.4 M) | (77.4 M) | (77.4 M) | (77.4 M) | (80.7 M) | (111.6 M) | (131.8 M) | (61.7 M) | (63.6 M) | (7.2 M) | 19.8 M | (58.4 M) | (92.5 M) | (207 M) | (168.6 M) | (151.8 M) | (144.2 M) |
| AZTA | 1.5 M | 136.8 M | (2.2 M) | 4.5 M | 14.2 M | (69.5 M) | 62.6 M | 116.6 M | 28.8 M | 64.9 M | 110.7 M | (429 M) | (14.3 M) | (164.9 M) | (55.8 M) | (64.1 M) | (67.3 M) |
| STAA | (3.8 M) | 1.3 M | (1.8 M) | 398 K | (8.4 M) | (6.5 M) | (12.1 M) | (2.1 M) | 5 M | 14 M | 5.9 M | 27.5 M | 39.7 M | 21.3 M | (20.2 M) | (23.2 M) | (22.1 M) |
| PHR | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (15.1 M) | (20.3 M) | (27.3 M) | (118.2 M) | (176.1 M) | (136.9 M) | (58.5 M) | (52.7 M) | (55.3 M) |
| PLSE | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (2.8 M) | (9.5 M) | (25.6 M) | (37.5 M) | (46 M) | (49.7 M) | (63.2 M) | (59 M) | (42.2 M) | (53.6 M) | (48.2 M) | (50.6 M) |
| NEOG | (1.1 M) | 22.5 M | 27.2 M | 28.2 M | 33.5 M | 36.6 M | 43.8 M | 63.1 M | 60.2 M | 59.5 M | 60.9 M | 48.3 M | (22.9 M) | (9.4 M) | (1.1 B) | (982.8 M) | (933.7 M) |
| HROW | (46.2 K) | (954 K) | (5.4 M) | (7.6 M) | (10.1 M) | (15.9 M) | (19.1 M) | (12 M) | 14.6 M | 168 K | (3.4 M) | (18 M) | (14.1 M) | (24.4 M) | (17.5 M) | (15.7 M) | (14.9 M) |
| ATRC | (3.6 M) | (5.5 M) | (7.5 M) | (11.5 M) | (16.2 M) | (27.2 M) | (33.3 M) | (26.9 M) | (21.1 M) | (35.2 M) | (48.2 M) | 50.2 M | (46.5 M) | (30.4 M) | (44.7 M) | (40.2 M) | (38.2 M) |
| ESTA | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (22.2 M) | (34.9 M) | (21.1 M) | (38.1 M) | (38.1 M) | (41.1 M) | (75.2 M) | (78.5 M) | (84.6 M) | (76.1 M) | (72.3 M) |
BioLife Solutions and related stocks such as Kestra Medical Techn, Novocure, and Azenta Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in BioLife Solutions financial statement analysis. It represents the amount of money remaining after all of BioLife Solutions operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| BioLife Solutions | BLFS |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 3303 Monte Villa |
| Exchange | NASDAQ Exchange |
USD 22.36
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.